Have you or your loved ones been diagnosed with non-muscle invasive bladder cancer (nmibc)?

You may be eligible to participate in a non-muscle invasive bladder cancer (nmibc) clinical trial.

Have you or your loved ones been diagnosed with non-muscle invasive bladder cancer (nmibc)? You may be eligible to participate in a non-muscle invasive bladder cancer (nmibc) clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Non-muscle Invasive Bladder Cancer (NMIBC) Clinical Trial
NCT03167151 | Phase 1 phase 2 | Interventional
University of Oxford
Sponsored by
University of Oxford

Have you or your loved ones been diagnosed with non-muscle invasive bladder cancer (nmibc)?

You may be eligible to participate in a non-muscle invasive bladder cancer (nmibc) clinical trial.

Have you or your loved ones been diagnosed with non-muscle invasive bladder cancer (nmibc)? You may be eligible to participate in a non-muscle invasive bladder cancer (nmibc) clinical trial.

Terminated

Male & Female

18 Years +

This study has recruited 6 Participants

A parallel group, open label, multi-centre, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab in recurrent intermediate risk NMIBC. Thirty patients (fifteen in each of two arms) will be randomised 1:1 to treatment with either intravesical pembrolizumab (Arm A) or intravenous pembrolizumab (Arm B). The main study will be preceded by a single institution safety run-in phase involving intra-patient dose escalation in six patients to confirm the safety and tolerability of intravesical pembrolizumab and the dose to be used in the randomised phase.